BRIEF published on 12/17/2025 at 11:02, 3 months 21 days ago Valerio Therapeutics Welcomes Professor Eric Vivier to its Board of Directors Board Of Directors Oncology Immunology Valerio Therapeutics Eric Vivier
BRIEF published on 12/17/2025 at 11:02, 3 months 21 days ago Valerio Therapeutics Accueille le Professeur Eric Vivier au Conseil d'Administration Conseil D'administration Oncologie Valerio Therapeutics Immunologie Eric Vivier
BRIEF published on 12/17/2025 at 11:02, 3 months 21 days ago Valerio Therapeutics nomme le professeur Eric Vivier observateur au conseil d'administration Conseil D'administration Valerio Thérapeutique Immunologie Professeur Eric Vivier Stratégie En Oncologie
BRIEF published on 12/17/2025 at 11:02, 3 months 21 days ago Valerio Therapeutics Appoints Professor Eric Vivier as Board Observer Board Of Directors Immunology Valerio Therapeutics Professor Eric Vivier Oncology Strategy
PRESS RELEASE published on 12/17/2025 at 10:57, 3 months 21 days ago Informations privilégiées / Autres communiqués Valerio Therapeutics annonce la désignation du Professeur Eric Vivier en qualité d'Observateur de son Conseil d’Administration. Le Professeur apportera son expertise en immunologie pour développer des traitements innovants en oncologie Conseil D'administration Valerio Therapeutics Immunologie Professeur Eric Vivier Observateur
PRESS RELEASE published on 12/17/2025 at 10:57, 3 months 21 days ago Inside Information / Other news releases Valerio Therapeutics appoints Prof. Eric Vivier as Observer to Board of Directors. Prof. Vivier, a renowned immunologist, will bring over 30 years of experience to drive innovative tumor treatment approaches Board Of Directors Valerio Therapeutics Professor Eric Vivier Immunologist Tumor Treatment
PRESS RELEASE published on 10/30/2025 at 09:04, 5 months 8 days ago Rapport financier semestriel 2025
BRIEF published on 10/30/2025 at 09:03, 5 months 8 days ago Bilan financier et stratégique de Valerio Therapeutics pour le 1er semestre 2025 Recentrage Stratégique Valerio Therapeutics Résultats Financiers 2025 Plateformes V-Body Recherche Partenariats
BRIEF published on 10/30/2025 at 09:03, 5 months 8 days ago Valerio Therapeutics' financial and strategic review for the first half of 2025 Strategic Refocusing Valerio Therapeutics 2025 Financial Results V-Body Platforms Seeking Partnerships
Published on 04/07/2026 at 15:00, 2 hours 11 minutes ago Karbon-X Expands Enterprise Climate Platform Through Strategic Partnership with carbon-connect AG
Published on 04/07/2026 at 14:45, 2 hours 26 minutes ago Predictiv AI Introduces Clinical AI Reasoning Platform, Files Patent for Domain-Specific Clinical AI Methodology
Published on 04/07/2026 at 14:40, 2 hours 31 minutes ago bioEnergy Development Inc. Advances Domestic Activated Carbon Production Worth Up to $30 Million Over 5 Years
Published on 04/07/2026 at 14:30, 2 hours 41 minutes ago Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
Published on 04/07/2026 at 14:30, 2 hours 41 minutes ago Sekur Private Data Announces Philip Oakley and Kenneth Rogers as Members of Strategic Advisory Board
Published on 04/07/2026 at 16:32, 38 minutes ago Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead’s oncology pipeline.
Published on 04/07/2026 at 16:30, 40 minutes ago From Old Channel to New Garden: How Chaoyang’s 'Sakura River' is Dazzling Spring
Published on 04/07/2026 at 15:00, 2 hours 11 minutes ago Amrize Announces Date for First Quarter 2026 Financial Results
Published on 04/07/2026 at 14:55, 2 hours 15 minutes ago Original-Research: Delticom AG (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 04/07/2026 at 14:42, 2 hours 28 minutes ago Evotec to Receive Approx. $100 Million as Part of Tubulis Acquisition
Published on 04/07/2026 at 16:43, 27 minutes ago Exercice de l’option de remboursement de l'instrument subordonné FR0010318386
Published on 04/07/2026 at 16:43, 27 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010318386
Published on 04/07/2026 at 16:18, 52 minutes ago NRJ Group - Information relative aux droits de vote au 31.03.2026 (French & English)
Published on 04/07/2026 at 14:44, 2 hours 26 minutes ago Statement of transactions in own shares from March 30, 2026 to April 2, 2026
